Yes, you are correct,
used to be with J&J, and am now with a small biotech. As far as what they think of CYGX, at J&J I brought up antisense and CYGX before and they were skitish about it...lack of efficacy stuff...I then explained the intracellular expression system and they were interested...all the people I knew in inflammation/anti-infectives in Raritan NJ were fired about a month ago.
my current company is an extremely small startup, with a focus on assay development for screening purposes agaist select targets within cancer, inflammation and neurodegenarative diseases...to try to find new drugs....really no use for gene silencing technologies...our is the old fashion compound/natural product screen.
News 
Market Data 
Discover 
AI
